<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928225</url>
  </required_header>
  <id_info>
    <org_study_id>QHPV-RTC</org_study_id>
    <nct_id>NCT01928225</nct_id>
  </id_info>
  <brief_title>Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL</brief_title>
  <official_title>A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Witwatersrand, South Africa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Witwatersrand, South Africa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor
      response to treatment of cervical cancer precursors. This study will test whether giving the
      quadrivalent vaccine to women prior to surgical treatment of the cervical cancer precursor
      will improve outcomes. We hypothesize that pre-treatment HPV vaccine will result in a reduced
      occurrence or cervical cancer precursors in follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, double-blinded, placebo-controlled, phase II trial of
      the quadrivalent human papillomavirus vaccine (qHPV) in HIV-infected women to prevent
      occurrence of cervical HSIL after LEEP/LLETZ. Participants will undergo colposcopy with
      directed biopsies, cervical cytology, and stored HPV testing prior to vaccination.
      Participants will be randomized to the quadrivalent vaccine or saline placebo to be given at
      entry, week 4, and week 26. Women will have LEEP treatment at week 4. Participants will be
      seen in follow-up for cervical cytology, colposcopy with directed biopsies at weeks 26 and
      52, and stored HPV specimens. Treatment assignment will be unblinded after study follow-up is
      completed for the last study participant. Women aged 45 or less randomized to placebo will be
      offered open label HPV vaccine after the study is concluded..
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2014</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical HSIL</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>For this trial, the primary endpoint is high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells suggestive of HSIL found on cervical cytology, or HSIL found on cervical biopsy specimens at either the week 26 or week 52 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cervical Cytology</measure>
    <time_frame>Week 26</time_frame>
    <description>Cervical cytology abnormalities according to the Bethesda scale. The Bethesda scale classifies cytologic abnormalities. We have dichotomized the outcomes into high grade squamous intraepithelial lesions (HSIL)/atypical squamous cells suggestive of HSIL, or no evidence of intraepithelial lesions or malignancy (NILM)/atypical squamous cells of unknown significance (ASC-US)/low grade squamous intraepithelial lesions (LSIL). We report the number of women in each category.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Cervical High Grade Squamous Intraepithelial Lesion</condition>
  <arm_group>
    <arm_group_label>Human Papillomavirus vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants receive saline placebo at entry, week 4 and week 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Papillomavirus vaccine</intervention_name>
    <description>The participants receive the qHPV vaccine at entry, week 4 and week 26</description>
    <arm_group_label>Human Papillomavirus vaccine</arm_group_label>
    <arm_group_label>Saline placebo</arm_group_label>
    <other_name>qHPV vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV infection

          2. Women aged ≥ 18 years.

          3. Cervical HSIL on biopsy (i.e. CIN2 and/or CIN3)

          4. For participants of reproductive potential, negative serum or urine pregnancy test

          5. All study participants must agree not to participate in a conception process (e.g.,
             active attempt to become pregnant or in vitro fertilization) during study
             participation (from the time of study entry until week 52).

        Exclusion Criteria:

          1. History or current biopsy diagnosis of invasive or microinvasive cervical, vaginal,
             vulvar, anal or oropharyngeal cancer

          2. Prior hysterectomy

          3. Cervical cryotherapy or LEEP/LEETZ within one year of entry.

          4. Cervical, vulvar, or vaginal lesions suspicious for cancer, unless biopsies show no
             invasive cancer

          5. Prior receipt of one or more doses of an HPV vaccine.

          6. Receipt of anticoagulants other than aspirin or nonsteroidal anti-inflammatory drugs
             (NSAIDS) within 14 days prior to entry.

          7. Known allergy/sensitivity or any hypersensitivity to yeast or any of the components of
             the study product or its formulation (see section 5.2 for a list of components).

          8. Hemophilia or other bleeding diatheses.

          9. Use of any systemic antineoplastic or immunomodulatory treatment, systemic
             corticosteroids, other than inhaled corticosteroids or prednisone ≤ 10 mg (or
             equivalent) , investigational vaccines, interleukins, interferons, growth factors, or
             intravenous immunoglobulin (IVIG) within 45 days prior to study entry.

         10. Breastfeeding

         11. Less than 3 months post-partum
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Wilkin, M.D. MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Firnhaber, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University or Witswatersrand</affiliation>
  </overall_official>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2013</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>June 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2020</results_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Witwatersrand, South Africa</investigator_affiliation>
    <investigator_full_name>Cynthia S Firnhaber</investigator_full_name>
    <investigator_title>Technical Director of the Clinical HIV Research Unit</investigator_title>
  </responsible_party>
  <keyword>HSIL</keyword>
  <keyword>CIN</keyword>
  <keyword>HPV</keyword>
  <keyword>HPV vaccination</keyword>
  <keyword>gardasil</keyword>
  <keyword>HIV</keyword>
  <keyword>cervical dysplasia</keyword>
  <keyword>LEEP</keyword>
  <keyword>cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT01928225/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Human Papillomavirus Vaccine</title>
          <description>Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
Human Papillomavirus vaccine: The participants receive the qHPV vaccine at entry, week 4 and week 26</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo</title>
          <description>The participants receive saline placebo at entry, week 4 and week 26.
Human Papillomavirus vaccine: The participants receive the qHPV vaccine at entry, week 4 and week 26</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>basaloid cervical cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Human Papillomavirus Vaccine</title>
          <description>Participants receive the quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo</title>
          <description>The participants receive saline placebo at entry, week 4 and week 26.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" lower_limit="34.8" upper_limit="46.6"/>
                    <measurement group_id="B2" value="39.1" lower_limit="35.2" upper_limit="44.2"/>
                    <measurement group_id="B3" value="39.2" lower_limit="34.9" upper_limit="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HSIL/ASC-H cervical cytology</title>
          <description>HSIL= high grade squamous intraepithelial lesions; ASC-H=atypical squamous cells suggestive of HSIL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma HIV-1 RNA &lt;200 copies/mL</title>
          <population>Plasma HIV RNA was missing on 17 participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4</title>
          <population>CD4 cell counts were missing on 17 participants</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="82"/>
                    <count group_id="B3" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="511" lower_limit="300" upper_limit="689"/>
                    <measurement group_id="B2" value="483" lower_limit="337" upper_limit="745"/>
                    <measurement group_id="B3" value="489" lower_limit="302" upper_limit="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nadir CD4</title>
          <population>Nadir CD4 counts were not available for two participants</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="89"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125" lower_limit="61" upper_limit="200"/>
                    <measurement group_id="B2" value="108" lower_limit="50" upper_limit="200"/>
                    <measurement group_id="B3" value="116" lower_limit="50" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cervical HSIL</title>
        <description>For this trial, the primary endpoint is high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells suggestive of HSIL found on cervical cytology, or HSIL found on cervical biopsy specimens at either the week 26 or week 52 visit.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Six participants did not have cytologic or histologic samples available for the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Human Papillomavirus Vaccine</title>
            <description>Participants receive the quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>The participants receive saline placebo at entry, week 4 and week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical HSIL</title>
          <description>For this trial, the primary endpoint is high-grade squamous intraepithelial lesions (HSIL) or atypical squamous cells suggestive of HSIL found on cervical cytology, or HSIL found on cervical biopsy specimens at either the week 26 or week 52 visit.</description>
          <population>Six participants did not have cytologic or histologic samples available for the primary endpoint</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.29</p_value>
            <p_value_desc>&lt;0.05 was considered statistically significant.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.87</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cervical Cytology</title>
        <description>Cervical cytology abnormalities according to the Bethesda scale. The Bethesda scale classifies cytologic abnormalities. We have dichotomized the outcomes into high grade squamous intraepithelial lesions (HSIL)/atypical squamous cells suggestive of HSIL, or no evidence of intraepithelial lesions or malignancy (NILM)/atypical squamous cells of unknown significance (ASC-US)/low grade squamous intraepithelial lesions (LSIL). We report the number of women in each category.</description>
        <time_frame>Week 26</time_frame>
        <population>Comparison of cytologic outcomes between arms at week 26. Nine participants are missing due to a missed visit, loss to follow-up, or unsatisfactory cytology result.</population>
        <group_list>
          <group group_id="O1">
            <title>Human Papillomavirus Vaccine</title>
            <description>Participants receive the experimental Human Papillomavirus vaccine at entry, week 4 and week 26.</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>The participants receive saline placebo at entry, week 4 and week 26.</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical Cytology</title>
          <description>Cervical cytology abnormalities according to the Bethesda scale. The Bethesda scale classifies cytologic abnormalities. We have dichotomized the outcomes into high grade squamous intraepithelial lesions (HSIL)/atypical squamous cells suggestive of HSIL, or no evidence of intraepithelial lesions or malignancy (NILM)/atypical squamous cells of unknown significance (ASC-US)/low grade squamous intraepithelial lesions (LSIL). We report the number of women in each category.</description>
          <population>Comparison of cytologic outcomes between arms at week 26. Nine participants are missing due to a missed visit, loss to follow-up, or unsatisfactory cytology result.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HSIL or ASC-H</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NILM/ASCUS/LSIL</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.22</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.85</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one year</time_frame>
      <desc>Grade 3 or 4 adverse event related to study vaccination. Please note that only deaths, serious adverse events, and grade 3 or 4 adverse events related to study vaccination were captured. Other grade 3 or 4 events were not captured per protocol. Grade 1 or 2 adverse events were not captured per protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Human Papillomavirus Vaccine</title>
          <description>Participants receive the experimental Human Papillomavirus vaccine at entry, week 4 and week 26.</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo</title>
          <description>The participants receive saline placebo at entry, week 4 and week 26.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>Death of unknown cause</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cervical cancer</sub_title>
                <description>Basaloid Cervical Cancer</description>
                <counts group_id="E1" events="90" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cynthia Frinhaber</name_or_title>
      <organization>University of Colorado</organization>
      <phone>720-848-0000</phone>
      <email>cynthia.firnhaber@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

